DMK
BLCM

David M. Knott’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

David M. Knott’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-16,820
Closed -$177K – 124
2019
Q3 		$177K Sell
16,820
-8,750
-34% -$114K 0.07% 80
2019
Q2 		$435K Buy
25,570
+12,957
+103% +$351K 0.18% 60
2019
Q1 		$425K Buy
12,613
+1,470
+13% +$49.1K 0.17% 63
2018
Q4 		$325K Buy
11,143
+2,110
+23% +$93.6K 0.15% 63
2018
Q3 		$556K Buy
9,033
+1,368
+18% +$92.6K 0.18% 60
2018
Q2 		$566K Buy
7,665
+900
+13% +$70.1K 0.21% 60
2018
Q1 		$444K Buy
6,765
+767
+13% +$57.9K 0.18% 64
2017
Q4 		$504K Buy
5,998
+300
+5% +$29.4K 0.2% 59
2017
Q3 		$658K Buy
5,698
+3,700
+185% +$389K 0.28% 47
2017
Q2 		$233K Buy
1,998
+940
+89% +$117K 0.1% 68
2017
Q1 		$131K Buy
+1,058
New +$139K 0.06% 53

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

David M. Knott's BLCM Position: Q4 2019 in Review

David M. Knott sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q4 2019, closing a stake of 16,820 shares — an estimated $177K sold.

David M. Knott first reported a position in BLCM in Q1 2017 and held it in 11 quarters. The position peaked at $658K in Q3 2017. 51 funds tracked by Wall St. Rank hold BLCM as of Q4 2019.

  • David M. Knott reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • David M. Knott sold 16,820 Bellicum Pharmaceuticals, Inc. shares in Q4 2019, an estimated $177K.
  • David M. Knott first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2017 and held it in 11 quarters.
  • David M. Knott's Bellicum Pharmaceuticals, Inc. position peaked at $658K in Q3 2017.
  • 51 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q4 2019.

Based on David M. Knott's 13F filing for Q4 2019, filed 14 Feb 2020.